Howrylak Judie A, Fuhlbrigge Anne L, Strunk Robert C, Zeiger Robert S, Weiss Scott T, Raby Benjamin A
J Allergy Clin Immunol. 2014 May;133(5):1289-300, 1300.e1-12. doi: 10.1016/j.jaci.2014.02.006.
Although recent studies have identified the presence of phenotypic clusters in asthmatic patients, the clinical significance and temporal stability of these clusters have not been explored.
Our aim was to examine the clinical relevance and temporal stability of phenotypic clusters in children with asthma.
We applied spectral clustering to clinical data from 1041 children with asthma participating in the Childhood Asthma Management Program. Posttreatment randomization follow-up data collected over 48 months were used to determine the effect of these clusters on pulmonary function and treatment response to inhaled anti-inflammatory medication.
We found 5 reproducible patient clusters that could be differentiated on the basis of 3 groups of features: atopic burden, degree of airway obstruction, and history of exacerbation. Cluster grouping predicted long-term asthma control, as measured by the need for oral prednisone (P < .0001) or additional controller medications (P = .001), as well as longitudinal differences in pulmonary function (P < .0001). We also found that the 2 clusters with the highest rates of exacerbation had different responses to inhaled corticosteroids when compared with the other clusters. One cluster demonstrated a positive response to both budesonide (P = .02) and nedocromil (P = .01) compared with placebo, whereas the other cluster demonstrated minimal responses to both budesonide (P = .12) and nedocromil (P = .56) compared with placebo.
Phenotypic clustering can be used to identify longitudinally consistent and clinically relevant patient subgroups, with implications for targeted therapeutic strategies and clinical trials design.
尽管最近的研究已经确定哮喘患者中存在表型聚类,但这些聚类的临床意义和时间稳定性尚未得到探索。
我们的目的是研究哮喘儿童表型聚类的临床相关性和时间稳定性。
我们将光谱聚类应用于参与儿童哮喘管理项目的1041名哮喘儿童的临床数据。使用48个月内收集的治疗后随机分组随访数据来确定这些聚类对肺功能和吸入抗炎药物治疗反应的影响。
我们发现了5个可重复的患者聚类,它们可以根据3组特征进行区分:特应性负担、气道阻塞程度和加重病史。聚类分组预测了长期哮喘控制情况,这通过口服泼尼松的需求(P <.0001)或额外的控制药物需求(P =.001)来衡量,以及肺功能的纵向差异(P <.0001)。我们还发现,与其他聚类相比,加重率最高的2个聚类对吸入性糖皮质激素有不同的反应。与安慰剂相比,一个聚类对布地奈德(P =.02)和奈多罗米(P =.01)均表现出阳性反应,而另一个聚类与安慰剂相比,对布地奈德(P =.12)和奈多罗米(P =.56)均表现出最小反应。
表型聚类可用于识别纵向一致且临床相关的患者亚组,这对靶向治疗策略和临床试验设计具有重要意义。